BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 556 filers reported holding BIO-TECHNE CORP in Q3 2021. The put-call ratio across all filers is 1.21 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $488 | -42.9% | 7,175 | -31.4% | 0.04% | -14.9% |
| Q2 2023 | $854 | +159.6% | 10,457 | +163.4% | 0.05% | +235.7% |
| Q1 2023 | $329 | 0.0% | 3,970 | 0.0% | 0.01% | 0.0% |
| Q4 2022 | $329 | -99.9% | 3,970 | +200.8% | 0.01% | -17.6% |
| Q3 2022 | $375,000 | -67.9% | 1,320 | -60.8% | 0.02% | -61.4% |
| Q2 2022 | $1,168,000 | -27.9% | 3,369 | -10.0% | 0.04% | -20.0% |
| Q1 2022 | $1,620,000 | -51.5% | 3,742 | -42.0% | 0.06% | -40.2% |
| Q4 2021 | $3,340,000 | +32.0% | 6,457 | +23.6% | 0.09% | +13.6% |
| Q3 2021 | $2,531,000 | +14.8% | 5,224 | +6.7% | 0.08% | +11.0% |
| Q2 2021 | $2,204,000 | +43.8% | 4,896 | +22.0% | 0.07% | +25.9% |
| Q1 2021 | $1,533,000 | +77.4% | 4,013 | +47.5% | 0.06% | +61.1% |
| Q4 2020 | $864,000 | +60.0% | 2,721 | +24.9% | 0.04% | +44.0% |
| Q3 2020 | $540,000 | -59.3% | 2,179 | -75.2% | 0.02% | -37.5% |
| Q1 2018 | $1,328,000 | +5.6% | 8,795 | -9.4% | 0.04% | +17.6% |
| Q4 2017 | $1,258,000 | -3.4% | 9,711 | -9.8% | 0.03% | -5.6% |
| Q3 2017 | $1,302,000 | -0.2% | 10,769 | -3.0% | 0.04% | -7.7% |
| Q2 2017 | $1,305,000 | +15.0% | 11,106 | -0.6% | 0.04% | +11.4% |
| Q1 2017 | $1,135,000 | +8.6% | 11,169 | +9.9% | 0.04% | +16.7% |
| Q4 2016 | $1,045,000 | +4.7% | 10,160 | +11.5% | 0.03% | -26.8% |
| Q3 2016 | $998,000 | +29.9% | 9,112 | +33.7% | 0.04% | +17.1% |
| Q2 2016 | $768,000 | +7.7% | 6,814 | -9.7% | 0.04% | +6.1% |
| Q1 2016 | $713,000 | 0.0% | 7,543 | -4.8% | 0.03% | +3.1% |
| Q4 2015 | $713,000 | -99.9% | 7,927 | -0.6% | 0.03% | -49.2% |
| Q3 2015 | $737,553,000 | +101212.2% | 7,977 | +7.9% | 0.06% | +75.0% |
| Q2 2015 | $728,000 | -21.8% | 7,394 | -20.5% | 0.04% | +71.4% |
| Q1 2015 | $931,000 | +1.5% | 9,300 | -6.3% | 0.02% | -62.5% |
| Q4 2014 | $917,000 | – | 9,924 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |